Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Revenue (2017 - 2025)

Historic Revenue for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $3.3 million.

  • Aclaris Therapeutics' Revenue fell 2409.11% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.7 million, marking a year-over-year decrease of 4186.85%. This contributed to the annual value of $18.7 million for FY2024, which is 4009.41% down from last year.
  • Aclaris Therapeutics' Revenue amounted to $3.3 million in Q3 2025, which was down 2409.11% from $1.8 million recorded in Q2 2025.
  • Over the past 5 years, Aclaris Therapeutics' Revenue peaked at $19.0 million during Q3 2022, and registered a low of $1.5 million during Q1 2022.
  • Over the past 5 years, Aclaris Therapeutics' median Revenue value was $2.4 million (recorded in 2024), while the average stood at $4.9 million.
  • In the last 5 years, Aclaris Therapeutics' Revenue skyrocketed by 104635.32% in 2022 and then plummeted by 5317.82% in 2024.
  • Over the past 5 years, Aclaris Therapeutics' Revenue (Quarter) stood at $1.5 million in 2021, then soared by 416.52% to $7.8 million in 2022, then soared by 126.62% to $17.6 million in 2023, then crashed by 47.58% to $9.2 million in 2024, then tumbled by 64.18% to $3.3 million in 2025.
  • Its Revenue stands at $3.3 million for Q3 2025, versus $1.8 million for Q2 2025 and $1.5 million for Q1 2025.